These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26323927)

  • 21. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.
    Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T
    Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis.
    Zhang N; Xie F; Gao W; Yu S; Qiu L; Lin W; Sun Y; Jia T
    Mol Med Rep; 2015 Apr; 11(4):2797-804. PubMed ID: 25504327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.
    Kubokura H; Tenjin T; Akiyama H; Koizumi K; Nishimura H; Yamamoto M; Tanaka S
    Ann Thorac Cardiovasc Surg; 2001 Aug; 7(4):197-203. PubMed ID: 11578259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MET: a new promising biomarker in non-small-cell lung carcinoma.
    Pérez-Ramírez C; Cañadas-Garre M; Jiménez-Varo E; Faus-Dáder MJ; Calleja-Hernández MÁ
    Pharmacogenomics; 2015; 16(6):631-47. PubMed ID: 25893986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
    Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A
    Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
    Suzuki M; Shiraishi K; Yoshida A; Shimada Y; Suzuki K; Asamura H; Furuta K; Kohno T; Tsuta K
    Lung Cancer; 2015 Jan; 87(1):14-22. PubMed ID: 25468202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The oncogenic role of PKCiota gene amplification and overexpression in Chinese non-small cell lung cancer.
    Luo Q; Tang L; Lin H; Huang J; Zhang T; Liu Y; Wang J; Zhan P; Yin X; Su X; Ji Q; Yu D; Xu L
    Lung Cancer; 2014 May; 84(2):190-5. PubMed ID: 24636699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?
    Kim ST; Jung HY; Sung JS; Jo UH; Tanaka T; Hagiwara K; Park KH; Shin SW; Kim JS; Kim YH
    Am J Clin Oncol; 2013 Feb; 36(1):57-63. PubMed ID: 22237146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of survivin levels in circulation and tissue samples of lung cancer patients.
    Kapellos G; Polonifi K; Farmakis D; Spartalis E; Tomos P; Aessopos A; Polizos A; Mantzourani M
    Anticancer Res; 2013 Aug; 33(8):3475-80. PubMed ID: 23898122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
    J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Study of gastric carcinoma and PCNA and c-met gene abnormality].
    Ji J; Zhao P; Huang B
    Wei Sheng Yan Jiu; 2008 Jul; 37(4):479-82. PubMed ID: 18839537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
    J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.
    Lee J; Seo JW; Jun HJ; Ki CS; Park SH; Park YS; Lim HY; Choi MG; Bae JM; Sohn TS; Noh JH; Kim S; Jang HL; Kim JY; Kim KM; Kang WK; Park JO
    Oncol Rep; 2011 Jun; 25(6):1517-24. PubMed ID: 21424128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lung Squamous Cell Carcinoma with De Novo c-Met Amplification.
    Lu H; Zheng G; Qian Q
    Clin Lab; 2017 Sep; 63(9):1519-1521. PubMed ID: 28879708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor.
    Lee C; Usenko D; Frampton GM; McMahon C; Ali SM; Weiss J
    J Thorac Oncol; 2015 Dec; 10(12):e113-4. PubMed ID: 26709483
    [No Abstract]   [Full Text] [Related]  

  • 39. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis.
    Shieh JM; Tang YA; Yang TH; Chen CY; Hsu HS; Tan YH; Salgia R; Wang YC
    Int J Med Sci; 2013; 10(8):988-94. PubMed ID: 23801885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Radial segmentation of lymphocytes in peripheral blood of patients with non-small cell lung cancer ].
    Dabrowska M; Domagała-Kulawik J; Kraszewska I; Chazan R
    Wiad Lek; 2002; 55(9-10):510-5. PubMed ID: 12607404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.